Neuronetics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.4%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$161.1Mnext fiscal year
FY EPS (est.)
-$0.47next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly34.5MTarget: Full-year 2026 revenue of $160 million to $166 million
U.S. Clinic Revenue Quarterly21.5MTarget: Continued expansion driven by Greenbrook integration and SPRAVATO buy-and-bill activity
NeuroStar Systems Shipped (US) Quarterly34.0Target: Increase system placements in high-volume accounts
GAAP Gross Margin Quarterly4,690.0%Target: Full-year 2026 gross margin of 47% to 49%
Watch Items
- Greenbrook Clinic Integration and Margin RecoveryTrigger: Gross margin falling below 45% or operating expenses exceeding $105 million annuallyAction: Accelerate cost structure alignment actions and optimize service-to-product mix.
- Operating Cash Flow Burn RateTrigger: Full-year operating cash flow burn exceeding negative $17 millionAction: Re-evaluate capital expenditures, renegotiate debt covenants, or implement further SG&A cost-saving measures.
- Payer Coverage ExpansionTrigger: Reversal or stagnation in policy expansions (e.g., Optum/UHC PMHNPs coverage)Action: Increase market access advocacy and leverage clinical registry data to demonstrate therapeutic efficacy.
Research as of 19 Jun 2026